Purple Biotech Ltd. Files 6-K on ATM Agreement
Ticker: PPBT · Form: 6-K · Filed: Jan 6, 2025 · CIK: 1614744
Sentiment: neutral
Topics: financing, equity-offering, atm-agreement
TL;DR
Purple Biotech's 6-K confirms ongoing ATM with Jefferies for stock sales.
AI Summary
Purple Biotech Ltd. is filing a Form 6-K for January 2025, reporting on its Open Market Sale Agreement (ATM Agreement) with Jefferies LLC, entered into on June 9, 2021. This agreement allows the company to offer shares of its common stock for sale.
Why It Matters
This filing provides an update on the company's ongoing equity financing arrangement, which could impact its capital structure and future share count.
Risk Assessment
Risk Level: low — The filing is a routine update on an existing financing agreement and does not introduce new material risks.
Key Players & Entities
- Purple Biotech Ltd. (company) — Filer of the 6-K
- Jefferies LLC (company) — Sales agent for the ATM Agreement
- June 9, 2021 (date) — Date the ATM Agreement was entered into
FAQ
What is the purpose of this Form 6-K filing?
The purpose of this Form 6-K is to report on the status of Purple Biotech Ltd.'s Open Market Sale Agreement with Jefferies LLC, entered into on June 9, 2021.
Who is the sales agent for the Open Market Sale Agreement?
Jefferies LLC is the sales agent for the Open Market Sale Agreement.
When was the Open Market Sale Agreement entered into?
The Open Market Sale Agreement was entered into on June 9, 2021.
What type of filing is this for Purple Biotech Ltd.?
This is a Form 6-K filing, which is a Report of Foreign Private Issuer.
Does Purple Biotech Ltd. file annual reports under Form 20-F or 40-F?
Purple Biotech Ltd. indicates it files annual reports under Form 20-F.
Filing Stats: 1,014 words · 4 min read · ~3 pages · Grade level 20 · Accepted 2025-01-06 17:26:02
Key Financial Figures
- $12.0 million — registered the offer and sale of up to $12.0 million of Shares. The prospectus supplement fi
- $3.0 million — e sold pursuant to the ATM Agreement to $3.0 million of Shares. As of the date hereof, the C
- $4.0 million — has sold an aggregate of approximately $4.0 million of Shares under the initial sales agree
- $1,330,000 — additional aggregate offering price of $1,330,000, from and after the date hereof. Becau
Filing Documents
- ea0226945-6k_purplebio.htm (6-K) — 17KB
- 0001213900-25-001241.txt ( ) — 18KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. January 6, 2025 PURPLE BIOTECH LTD. By: /s/ Gil Efron Gil Efron Chief Executive Officer 2